https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19332
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADSofosbuvir / Velpatasvir / Voxilaprevir can inhibit OATP1B1 and increase the plasma concentration of Voxilaprevir Lovastatin.
–
–
–
Possible increase of adverse effects.
Increased risk of myopathy and rhabdomyolysis.
Use this combination with caution.
Use the smallest dose as possible.
Monitor closely for adverse effects.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
CK
Lipidic profile
–
–